{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:13:45Z","timestamp":1794366825989,"version":"4.9.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2025.117241","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T19:45:01Z","timestamp":1736019901000},"page":"117241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["New FDA drug approvals for 2024: Synthesis and clinical application"],"prefix":"10.1016","volume":"285","author":[{"given":"Yingying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baizhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117241_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.58347\/tml.2024.1707d","volume":"66","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.ejmech.2025.117241_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/00185787241269112","article-title":"Cefepime\/enmetazobactam","volume":"59","author":"Staten","year":"2024","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.ejmech.2025.117241_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40265-024-02035-2","article-title":"Cefepime\/enmetazobactam: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib4","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117241_bib6","article-title":"The trend of cefepime-induced neurotoxicity: a systematic review","volume":"15","author":"Ajibola","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejmech.2025.117241_bib7","series-title":"Process for the Direct Preparation of Cefepime for Injectable Use","author":"Alberto","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117241_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/10600280241279904","article-title":"Cefepime-enmetazobactam: a drug review of a novel beta-lactam\/beta-lactamase inhibitor","author":"Lanier","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.117241_bib9","series-title":"Compounds and Their Use","author":"Udayampalayam Palanisamy","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117241_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.clinthera.2024.06.007","article-title":"Ceftobiprole Medocaril Sodium","volume":"46","author":"Beninger","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejmech.2025.117241_bib11","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","article-title":"Ceftobiprole: drug evaluation and place in therapy","volume":"17","author":"Giacobbe","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ejmech.2025.117241_bib13","series-title":"Method for the Production of Ceftobiprole Medocaril","author":"Kremminger","year":"2010"},{"key":"10.1016\/j.ejmech.2025.117241_bib14","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib15","series-title":"Preparation of Sulopenem Prodrugs for the Treatment of Bacterial Infection","author":"Brighty","year":"2008"},{"key":"10.1016\/j.ejmech.2025.117241_bib16","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib17","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases","article-title":"Clinical and research information on drug-induced liver injury","author":"Probenecid","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117241_bib18","series-title":"(Dialkylsulfamyl)benzoic Acids","first-page":"US2608507A","author":"Miller","year":"1952"},{"key":"10.1016\/j.ejmech.2025.117241_bib19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-024-02069-6","article-title":"Tovorafenib: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib20","series-title":"Pyrimidine-4-carboxamide Compounds Useful as Raf Kinase Inhibitors and Their Preparation and Use in the Treatment of Raf-Mediated Diseases","author":"Chen","year":"2009"},{"key":"10.1016\/j.ejmech.2025.117241_bib21","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","article-title":"Vorasidenib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib22","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.47391\/JPMA.20428","article-title":"Vorasidenib- A paradigm shift in IDH1- or IDH2-mutant low-grade glioma treatment","volume":"74","author":"Malik","year":"2024","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.ejmech.2025.117241_bib23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41571-024-00944-5","article-title":"Vorasidenib: a new hope or a false promise for patients with low-grade glioma?","volume":"21","author":"Lazarev","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117241_bib24","series-title":"Therapeutically Active Compounds and Their Methods of Use","author":"Konteatis","year":"2015"},{"key":"10.1016\/j.ejmech.2025.117241_bib25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40265-021-01533-x","article-title":"Lazertinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11910-024-01388-1","article-title":"Emerging therapies for brain metastases in NSCLC, breast cancer, and melanoma: a critical review","volume":"25","author":"Podder","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ejmech.2025.117241_bib27","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non\u2013small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117241_bib28","series-title":"Improved Process for Preparing Lazertinib and Intermediates Thereof","author":"Oh","year":"2019"},{"key":"10.1016\/j.ejmech.2025.117241_bib29","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.58347\/tml.2024.1715f","article-title":"Inavolisib (Itovebi) for locally advanced or metastatic breast cancer","volume":"66","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.ejmech.2025.117241_bib30","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","article-title":"Discovery of GDC-0077 (inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1","volume":"65","author":"Hanan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117241_bib31","first-page":"1","article-title":"Preclinical assessment of the PI3K\u03b1 selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human","author":"Salphati","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2025.117241_bib32","series-title":"Process for the Preparation of Benzoxazepin Oxazolidinone Compounds","author":"Angelaud","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117241_bib33","first-page":"3488","article-title":"Revumenib for patients with acute leukemia: a new tool for differentiation therapy","volume":"109","author":"Salman","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.117241_bib34","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1097\/MS9.0000000000001888","article-title":"Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML)","volume":"86","author":"Hussain","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.ejmech.2025.117241_bib35","series-title":"Preparation of Inhibitors of the Menin-MLL Interaction","author":"Cacatian","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117241_bib36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/13543776.2023.2216381","article-title":"An updated patent review of anaplastic lymphoma kinase inhibitors (2018-2022)","volume":"33","author":"Ma","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.117241_bib37","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1021\/jm3009103","article-title":"The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl) oxy] ethoxy]-4-pyrimidinyl]-N\u2032-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist","volume":"55","author":"Bolli","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117241_bib38","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-024-02053-0","article-title":"Aprocitentan: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1139\/cjpp-2022-0010","article-title":"Aprocitentan and the endothelin system in resistant hypertension","volume":"100","author":"Clozel","year":"2022","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117241_bib41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ajhp\/zxae142","volume":"81","year":"2024","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2025.117241_bib42","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40265-024-02023-6","article-title":"Danicopan: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib43","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/cpt.3342","article-title":"Pharmacokinetics, pharmacodynamics, and safety of vadadustat in healthy volunteers and patients with chronic kidney disease","volume":"116","author":"Navarro-Gonzales","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117241_bib44","series-title":"Preparation of Stable Crystalline Forms of Complement Factor D Inhibitors for Therapeutic Use","author":"Phadke","year":"2020"},{"key":"10.1016\/j.ejmech.2025.117241_bib45","series-title":"Acoramidis: A Promising Drug for Transthyretin Amyloid Cardiomyopathy","first-page":"1","author":"Bin Faheem","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117241_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117241_bib47","first-page":"1346","article-title":"Acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Groothof","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117241_bib48","series-title":"Compounds and Compositions that Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions","author":"Graef","year":"2014"},{"key":"10.1016\/j.ejmech.2025.117241_bib49","article-title":"Landiolol for treating arrhythmias: a state-of-the-art review","volume":"15","author":"Ghallab","year":"2024","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ejmech.2025.117241_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-018-0883-9","article-title":"Landiolol: a review in tachyarrhythmias","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib51","series-title":"Preparation of Phenylalkanoate Esters as Cardiovascular Agents","author":"Iguchi","year":"1990"},{"key":"10.1016\/j.ejmech.2025.117241_bib52","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","article-title":"Vadadustat: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib53","series-title":"Preparation of [(3-Hydroxypyridine-2-Carbonyl)amino]alkanoic Acids, Esters and Amides as Prolyl Hydroxylase Inhibitors","author":"Lanthier","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117241_bib54","author":"Citrate","year":"2024","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2025.117241_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2024.10.010","article-title":"Miplyffa (arimoclomol)","author":"Beninger","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejmech.2025.117241_bib56","series-title":"Processes for Preparing Arimoclomol Citrate and Intermediates Thereof","author":"Zhang","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117241_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2024.10.011","article-title":"Aqneursa (levacetylleucine)","author":"Beninger","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejmech.2025.117241_bib58","series-title":"Modulators of Sestrin-Gator2 Interaction and Uses Thereof","author":"Fetalvero","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117241_bib59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.58347\/tml.2024.1715a","volume":"66","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.ejmech.2025.117241_bib60","article-title":"Cobenfy: a new ray of hope in schizophrenia treatment","volume":"103","author":"Noor","year":"2024","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.ejmech.2025.117241_bib61","first-page":"1","article-title":"A new antipsychotic for schizophenia: xanomeline and trospium (cobenfy)","author":"Mills","year":"2024","journal-title":"Issues Ment. Health Nurs."},{"key":"10.1016\/j.ejmech.2025.117241_bib62","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib63","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/acschemneuro.7b00001","article-title":"Classics in chemical neuroscience: xanomeline","volume":"8","author":"Bender","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117241_bib64","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1021\/jm00090a019","article-title":"Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1, 2, 5-thiadiazolyl)-1, 2, 5, 6-tetrahydro-1-methylpyridines","volume":"35","author":"Sauerberg","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117241_bib65","article-title":"Cobenfy (Xanomeline-Trospium chloride): a new frontier in schizophrenia management","volume":"16","author":"Hasan","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejmech.2025.117241_bib66","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.clinthera.2024.10.001","article-title":"Xanomeline and trospium chloride","volume":"46","author":"Beninger","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejmech.2025.117241_bib67","first-page":"714","article-title":"On azoniaspire-compounds. 1","volume":"17","author":"Bertholdt","year":"1967","journal-title":"Preparation of non-esterified azoniaspire-compounds of nortropan-3alpha-or 3beta-ol"},{"key":"10.1016\/j.ejmech.2025.117241_bib68","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","article-title":"The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene","volume":"11","author":"Licandro","year":"2021","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.ejmech.2025.117241_bib70","series-title":"Preparation of Benzohydroxamic Acids as Antiinflammatory and Immunosuppressive Agents","author":"Bertolini","year":"1997"},{"key":"10.1016\/j.ejmech.2025.117241_bib71","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2020.05.063","article-title":"Phase-III clinical trial of fluorine-18 flurpiridaz positron emission tomography for evaluation of coronary artery disease","volume":"76","author":"Maddahi","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2025.117241_bib72","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2023.08.016","article-title":"Flurpiridaz F-18 PET myocardial perfusion imaging in patients with suspected coronary artery disease","volume":"82","author":"Maddahi","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2025.117241_bib73","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s11886-022-01713-5","article-title":"The potential of F-18 flurpiridaz PET\/CT myocardial perfusion imaging for precision imaging","volume":"24","author":"Patel","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ejmech.2025.117241_bib74","series-title":"Methods of Making Radiolabeled Tracers and Precursors Thereof","author":"Casebier","year":"2007"},{"key":"10.1016\/j.ejmech.2025.117241_bib75","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib76","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.radi.2024.05.003","article-title":"Stability testing of iomeprol and iopamidol formulations subjected to X-ray radiation","volume":"30","author":"Colombo Serra","year":"2024","journal-title":"Radiography"},{"key":"10.1016\/j.ejmech.2025.117241_bib77","series-title":"A Method for Preparing Iomeprol","author":"Zou","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117241_bib78","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-024-02075-8","article-title":"Elafibranor: first approval","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib79","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases","article-title":"Clinical and research information on drug-induced liver injury","author":"Elafibranor","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117241_bib80","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41575-023-00878-w","article-title":"Elafibranor in primary biliary cholangitis","volume":"21","author":"Kotsiliti","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.117241_bib81","series-title":"Preparation of 1,3-diphenyl Prop-2-En-1-One Derivatives","author":"Jean-Frangois Delhomel","year":"2008"},{"key":"10.1016\/j.ejmech.2025.117241_bib82","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-024-02114-4","article-title":"Seladelpar: first approval","volume":"84","author":"Hoy","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib83","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases","article-title":"Clinical and research information on drug-induced liver injury","author":"Seladelpar","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117241_bib84","series-title":"Preparation of 4-((phenoxyalkyl)thio)phenoxyacetic Acids and Analogs as PPAR\u03b4 Agonists for Treating Conditions like Dyslipidemia","author":"Kuo","year":"2005"},{"key":"10.1016\/j.ejmech.2025.117241_bib85","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s40265-024-02063-y","article-title":"Mavorixafor: first approval","volume":"84","author":"Hoy","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib86","series-title":"Rocess for the Synthesis of Benzimidazoles as CXCR4 Antagonist","article-title":"P","author":"Crawford","year":"2005"},{"key":"10.1016\/j.ejmech.2025.117241_bib87","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib88","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases","article-title":"Clinical and research information on drug-induced liver injury","author":"Deuruxolitinib","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117241_bib89","series-title":"Process for Preparing Enantiomerically Enriched JAK Inhibitors","author":"Lewis","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117241_bib90","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s40265-020-01438-1","article-title":"Sofpironium Bromide: first approval","volume":"80","author":"Paik","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib91","series-title":"Soft Anticholinergic Esters","author":"Bodor","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117241_bib92","first-page":"1557","article-title":"Crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Jaschke","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117241_bib93","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"3, 4, 5-tetrahydro [1, 2, 4] triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117241_bib94","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40265-024-02081-w","article-title":"Ensifentrine: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117241_bib95","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2147\/COPD.S413436","article-title":"Ensifentrine as a novel, inhaled treatment for patients with COPD","volume":"18","author":"Donohue","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejmech.2025.117241_bib96","series-title":"Preparation of 2-Aryliminopyrimido[6,1-A]isoquinolin-4-Ones as Phosphodiesterase Inhibitors","author":"Oxford","year":"2000"},{"key":"10.1016\/j.ejmech.2025.117241_bib97","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117241_bib98","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases","article-title":"Clinical and research information on drug-induced liver injury","author":"Resmetirom","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117241_bib99","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV Endocrinol"},{"key":"10.1016\/j.ejmech.2025.117241_bib100","series-title":"Ivacaftor, Drugs and Lactation Database (LactMed\u00ae)","author":"Elexacaftor","year":"2006"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T21:01:00Z","timestamp":1740344460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":100,"alternative-id":["S0223523425000066"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117241","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New FDA drug approvals for 2024: Synthesis and clinical application","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117241"}}